Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells 6,239 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 6,239 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $278,259.40. Following the completion of the sale, the chief operating officer now owns 231,401 shares in the company, valued at $10,320,484.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total value of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $296,636.65.

Twist Bioscience Stock Down 0.3 %

Shares of TWST stock traded down $0.12 during trading hours on Friday, hitting $45.40. 638,544 shares of the company’s stock traded hands, compared to its average volume of 941,083. The stock has a market cap of $2.66 billion, a PE ratio of -11.92 and a beta of 1.78. Twist Bioscience Co. has a 12 month low of $15.85 and a 12 month high of $60.90. The stock’s 50 day simple moving average is $43.65 and its 200 day simple moving average is $45.43.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently made changes to their positions in the stock. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the period. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the second quarter worth approximately $43,000. Blue Trust Inc. lifted its stake in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Leerink Partners boosted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Finally, Barclays decreased their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.